Abstract 72P
Background
Traditional genetic screening was based previously on the analysis of classical high penetrance genes such as BRCA1 and BRCA2. In the context of our clinical practice in Dubai, individuals fulfilling the criteria are tested for germline mutations to subsequently establish the clinical management. Our current standard diagnostic approach focuses on sequencing 110 genes through NGS leading to increase the chance of finding the causal mutation and to the widespread clinical use of genes for germline cancer testing.
Methods
A total of 111 cases were tested in UAE with a traditional panel (BRCA1, BRCA2 and CHEK2) from October 2013 till September 2016. Then we have integrated extended panels (36 then 110 genes) from October 2016 till March 2023 and tested 509 cases. Median age was 47 years. Cases were referred for genetic testing mainly due to personal history of breast and ovarian cancer.
Results
Mutations in traditionally screened cases represent 8.1% for BRCA1, BRCA2 and 1% for CHEK2 for all types of panels. However extended panel analysis had a higher detection rate of pathogenic mutations compared to traditional analysis with an average increase of 7% in several genes mainly MUTYH, TP53, MLH1, RAD51D, PALB2 (respectively 2.6%, 0.8%, 0.8%, 0.6%, 0.6%). The heterogeneity of the newly detected mutations identified reinforces the value of using an extended hereditary panel. Further analysis will correlate the characteristics of germline mutations and their correlation with the tumor type and with the age group.
Conclusions
To our knowledge this is the first abstract from the MEA focusing on the impact of the analysis of extended panel of genes to patients with suspicion of hereditary cancer. Our findings reinforce the utility of extended panels involved in hereditary cancer predisposition in the diagnostic routine which may impact their clinical management. The use of this approach facilitates the detection of pathogenic mutations in non-BRCA1/2 genes and aided management. This will allow opportunities for enhanced surveillance and intervention in a range of tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IPS Genomix.
Funding
Has not received any funding.
Disclosure
S. Dawood: Financial Interests, Personal, Speaker, Consultant, Advisor: Newbridge, Caris Life Sciences, Janssen, BMS, Lilly, MSD, AstraZeneca, Pfizer, Novartis, Ipsen; Financial Interests, Personal, Other, Clinical studies: AZ; Financial Interests, Personal, Research Grant: MSD, Amgen. M. Wasfy, R. Khoury: Financial Interests, Personal, Full or part-time Employment: IPS Genomix.
Resources from the same session
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09
15P - CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Presenter: Luisa Chocarro
Session: Poster session 09
16P - Terminally exhausted CD8+ T cells and increased immunosuppressive soluble factors in malignant ascites of patients with gastric cancer with peritoneal metastasis
Presenter: Hye Sook Han
Session: Poster session 09
17P - Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Presenter: Robert Watson
Session: Poster session 09
18P - Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Presenter: Alessandro Cavaliere
Session: Poster session 09
19P - Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Presenter: Yanelys Morera
Session: Poster session 09
20P - The essential role of DNA repair in the pharmacological activities of AST-3424
Presenter: Fanying Meng
Session: Poster session 09
21P - Implications of KMT2C knockdown for DNA damage repair in breast cancer
Presenter: Philip Bredin
Session: Poster session 09
22P - Clinical significance of DNA damage response mutations in early stage NSCLC
Presenter: Haoran Zhang
Session: Poster session 09
23P - PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
Presenter: Cheon Ho Park
Session: Poster session 09